Connect with us
[bsa_pro_ad_space id=12]

Daily Caller

RFK’s Calls To Ban One Of Big Pharma’s Most Powerful Tools Rattle Drugmakers Despite Uncertain Political Prospects

Published

7 months ago

11 minute read

 

From the Daily Caller News Foundation

By Adam Pack

“The primary purpose of pharmaceutical advertising is not to influence consumers, but rather the television networks and news itself”

President-elect Donald Trump’s nomination of Robert F. Kennedy Jr. to helm the Department of Health and Human Services(HHS) is reportedly rattling drugmakers in light of Kennedy’s prior calls to ban pharmaceutical advertising.

If confirmed by the Senate to serve as HHS secretary, Kennedy could marshal the country’s public health agencies to implement his Make America Healthy Again (MAHA) priorities, leading one pharmaceutical industry observer to claim that Kennedy is likely to attempt a ban on direct-to-consumer (DTC) drug advertising. However, any attempt from Kennedy to crack down on pharmaceutical advertising would almost certainly be challenged by drugmakers on First Amendment grounds and may lack the support of Trump and Republican lawmakers who have so far refrained from commenting on Kennedy’s proposal.

“One of the things I’m going to advise Donald Trump to do in order to correct the chronic disease epidemic is to ban pharmaceutical advertising on TV,” Kennedy said to thunderous applause during a Tucker Carlson Live Tour event in Glendale, Arizona, on Oct. 31. “There’s only two countries in the world that allow pharmaceutical advertising on the airwaves. One of them is New Zealand and the other is us and we have the highest disease rate, and we buy more drugs and they’re more expensive than anywhere in the world.”

 

Spending on DTC pharmaceutical advertising in the United States ballooned to more than $7 billion in 2023, with ad buys  on weight loss and diabetes drugs surpassing $1 billion for the first time, according to analysis from MediaRadar.

‘Threat To The Public Good’ 

“Whilst we have a relatively benign view of RFK’s impact on the Pharma industry, one thing that does worry us is the potential for the U.S. government to ban DTC advertising of drugs,” United Kingdom-based research firm Intron Health wrote in a report excerpted by FiercePharma, a pharmaceutical industry-focused news outlet. “We see this as the biggest imminent threat from RFK and the new Trump administration.”

Kennedy could wield considerable influence over the second Trump administration’s approach to pharmaceutical advertising since the Food and Drug Administration (FDA) — the chief regulator of the pharmaceutical industry’s advertisements — is housed within HHS.

The Biden FDA issued new guidelines on DTC advertising that went into effect on May 20, requiring advertising to state drugs’ side effects and medication risks in a “clear, conspicuous, and neutral manner.” Kennedy called for a review of these guidelines in an op-ed in The Wall Street Journal published on Sept. 5.

During his run for president and as a Trump campaign surrogate, Kennedy claimed that media outlets who receive substantial ad revenue from pharmaceutical companies cannot report on Big Pharma with objectivity.

“The primary purpose of pharmaceutical advertising is not to influence consumers, but rather the television networks and news itself,” according to a statement on Kennedy’s website. “It gives Big Pharma the power to dictate what goes on the news — and what doesn’t — because the networks won’t bite the hand that feeds them.”

“Every other country in the world recognizes that pharma ads represent a threat to the public good,” Kennedy’s website also claims.

Kennedy’s concern that mainstream media has been co-opted by the pharmaceutical industry to buy news outlets’ silence on scrutinizing drugmakers in exchange for ad revenue has been embraced by influential voices in the MAHA movement and other Trump allies.

“The news ad spending from pharma is a public relations lobbying tactic, essentially to buy off the news,” Calley Means, a Kennedy advisor and MAHA advocate, told Tucker Carlson during an interview on Feb 2. “The news is not investigating pharma.”

“No advertising for pharma,” Elon Musk wrote on X on Nov. 19 in response to a post alleging a correlation between the growth of pharmaceutical advertising and rising media bias.

Dr. Jay Bhattacharya, Trump’s nominee to lead the National Institutes of Health, has also argued that media organizations that rake in pharmaceutical advertising revenue should face increased scrutiny when reporting on public health matters. Bhattacharya was notably blacklisted by Twitter before Musk bought the platform over his criticism of the medical establishment’s lockdown approach to the COVID-19 pandemic.

“Another argument against direct-to-consumer advertising by drug companies: Because of DTC ads, drug companies like Pfizer hold a vice grip on the editorial policies of conventional American media, which can ill afford to lose the advertising money,” Bhattacharya wrote on X on May 30, 2023.

 

Dr. Marty Mackary, Trump’s pick to lead the FDA, has not commented on Kennedy’s proposal nor allegations that the mainstream media has been corrupted by the pharmaceutical industry.

Ban Denies ‘Opportunity To Be Informed’

Although a ban on pharmaceutical advertising would put the U.S. more in line with the rest of the world, an attempted prohibition of the practice by the incoming Trump administration would likely infringe upon the First Amendment’s protection of “commercial speech,” according to Dr. Jeffrey Singer, a general surgeon and senior fellow at the libertarian-leaning Cato Institute.

“His calls to ban pharmaceutical advertising violate the First Amendment right to freely share and exchange information, including scientific information, and infringe on the individual right to self-medicate,” Singer wrote in a statement following Trump’s nomination of Kennedy to serve as HHS secretary.

Banning pharmaceutical advertising would also make Americans less informed about the availability of drugs and their side effects and widen the information gap between medical practitioners and patients, an apparent contradiction to Kennedy’s pledge to fight for Americans’ ability to question the medical establishment and do their own research, Singer told the Daily Caller News Foundation in an interview.

“On the one hand, RFK Jr. says — and I agree with him — that people need to be empowered. They need to do their own due diligence. We should be doing our own investigations,” Singer told the DCNF. “Well, how are you going to do that if you are barred from hearing what the pharmaceutical companies have to say about their medication, and its risks and benefits and side effects, which the FDA requires them to mention?”

“If you want an empowered population of adults to be able to do their own due diligence, you can’t block them from the information that a pharmaceutical [ad] is going to give them — especially when they’re [pharmaceutical companies] allowed to give it to healthcare practitioners,” Singer added. “Denying us the information actually denies us the opportunity to be informed.”

Uncertain Political Prospects

Kennedy’s call to ban pharmaceutical advertising is likely to face skepticism from Republican lawmakers who have traditionally preferred a deregulatory approach to the pharmaceutical industry. The current legislative effort to ban DTC pharmaceutical advertising in Congress has no support from Republican lawmakers.

“Sometimes when I hear his [Kennedy’s] agenda discussed, people are like ‘sounds great — he’s never going to do it’. There’s zero chance he’s going to be able to undo these conflicts of interests and the power of Big Ag and these Republican lawmakers who have a lot of big donors in these industries,” Megyn Kelly told Casey Means, during a Nov. 20 interview on her show about whether Kennedy’s MAHA priorities have enough support to be achieved during the next four years.

The pharmaceutical industry notably has roughly 1800 registered lobbyists in the United States, and industry PACs have doled out more than $15 million to candidates this year.

Trump tried to further regulate pharmaceutical advertising during his first administration by requiring DTC ads on television to include the list price for nearly all drugs covered by Medicare and Medicaid. Three large drugmakers filed suit in response and a federal judge struck down the regulation before it went into effect, ruling that HHS overstepped its authority to compel drugmakers to include their list prices in advertising.

Trump’s transition team did not respond to the DCNF’s inquiry about whether the president-elect supports Kennedy’s advocacy to crack down on pharmaceutical advertising.

The Pharmaceutical Research and Manufacturers of America, a trade association that lobbies on behalf of the pharmaceutical industry, declined to comment on Kennedy’s calls to ban pharmaceutical advertising.

A Kennedy spokesperson did not respond to the DCNF’s request for comment.

Related Topics:

Todayville is a digital media and technology company. We profile unique stories and events in our community. Register and promote your community event for free.

Follow Author

More from this author
Business / 8 mins ago

WEF-linked Linda Yaccarino to step down as CEO of X

Crime / 8 hours ago

Tucker Carlson: US intelligence is shielding Epstein network, not President Trump

Freedom Convoy / 8 hours ago

Court Orders Bank Freezing Records in Freedom Convoy Case

Daily Caller

USAID Quietly Sent Thousands Of Viruses To Chinese Military-Linked Biolab

Published on July 9, 2025

By

 

From the Daily Caller News Foundation

By Emily Kopp

The U.S. Agency for International Development (USAID) shipped thousands of viral samples to a lab in Wuhan over the course of a 10-year program even though it had no formal agreement with the lab in place, according to previously unreported documents.

The documents show that USAID funded the exportation of 11,000 samples from Yunnan Province, where some of the closest relatives of the COVID-19 virus circulate, to Wuhan, the epicenter of the pandemic, with no apparent plan for ensuring the samples were not misdirected to bioweapons and remained accessible to the U.S. government.

A $210 million USAID public health program called PREDICT, steered by the University of California-Davis, collected viral samples in countries throughout the globe but lacked long-term storage when funding dried up, according to rudimentary plans in 2019.

Dear Readers:

As a nonprofit, we are dependent on the generosity of our readers.

Please consider making a small donation of any amount here.

Thank you!

USAID’s sample dispensation plan for China is sparse: “No need [sic] information from Yunnan. They were never an official lab partner for PREDICT. All samples they helped collected [sic] are sent to, tested, and stored in Wuhan.”

The “lab” refers to the Wuhan Institute of Virology (WIV). WIV was a close partner of USAID contractor EcoHealth Alliance and a slated partner for a PREDICT-like program supported by the State Department. The lab has poor biosafety practices and ties to the People’s Liberation Army (PLA). 

One of the closest known relatives of the COVID virus is among the viruses sampled with USAID funding.

“Investigations involving USAID’s former funding of global health awards remain active and ongoing,” a senior State Department official said in a statement to the Daily Caller News Foundation. “The American people can rest assured knowing that under the Trump Administration we will not be funding these controversial programs.”

The internal documents were obtained through a FOIA lawsuit brought by U.S. Right to Know, a nonprofit newsroom and public health research group.

The shuttering of USAID – which was officially completed Tuesday – has ignited a debate about its net impact on global health. A study in The Lancet projected an association between a dropoff in USAID funding and 14 million deaths based on an epidemiological model.

Secretary of State Marco Rubio said in a statement Tuesday that USAID spending has often undermined rather than strengthened American interests.

“Beyond creating a globe-spanning NGO industrial complex at taxpayer expense, USAID has little to show since the end of the Cold War,” Rubio said. “Development objectives have rarely been met, instability has often worsened, and anti-American sentiment has only grown.”

The now-defunct agency’s connection to the Wuhan lab complicates its global health legacy.

“The USAID $210 million contract for PREDICT should have included contractual terms that required all samples, or at least copies of all samples, be transferred to and stored by a US government facility,” said Rutgers University molecular biologist Richard Ebright told the DCNF. “The PREDICT grift did none of this.”

UC Davis did not respond to a request for comment. The State Department did not respond to a request for comment.

Did USAID Fund COVID’s Ancestor?

Many of the viruses stored at the lab in Wuhan may have been sampled with U.S. funding yet remain out of reach for U.S. government entities investigating the origins of COVID.

The samples were set to be preserved for testing – with human samples preserved for 10 years – the documents show. But the documents suggest that requirement was never incorporated into a formal contract with USAID.

The two scientists supervising the samples were: Ben Hu, a virologist at the WIV, who reportedly became sick with COVID-like symptoms in 2019; and Peter Daszak, a scientist who was debarred from federal funding after the U.S. government deemed him a threat to public safety for inadequate oversight of the research in Wuhan.

Hu and Daszak did not reply to requests for comment.

The documents show PREDICT contractors discussing viral samples taken from wildlife and stored in India, Liberia, Malaysia, the Republic of Congo and China. Some of the samples were stored in virus-transport media (VTM), which allows researchers to store live viruses for later use in the lab.

“It’s not rocket science to require a contract and supporting paperwork which establishes a relationship, testing protocol, and chain of custody, when one is sending out lab samples,” said Reuben Guttman, a partner at Guttman, Buschner & Brooks PLLC who specializes in ensuring the integrity of government programs, in an interview with the DCNF. “In any scientific endeavor, you need confidence in your results. That requires paperwork to prove your methodology is sound.”

Continue Reading

Daily Caller

Trump Issues Order To End Green Energy Gravy Train, Cites National Security

Published on July 9, 2025

By

 

From the Daily Caller News Foundation

By Audrey Streb

President Donald Trump issued an executive order calling for the end of green energy subsidies by strengthening provisions in the One Big Beautiful Bill Act on Monday night, citing national security concerns and unnecessary costs to taxpayers.

The order argues that a heavy reliance on green energy subsidies compromise the reliability of the power grid and undermines energy independence. Trump called for the U.S. to “rapidly eliminate” federal green energy subsidies and to “build upon and strengthen” the repeal of wind and solar tax credits remaining in the reconciliation law in the order, directing the Treasury Department to enforce the phase-out of tax credits.

“For too long, the Federal Government has forced American taxpayers to subsidize expensive and unreliable energy sources like wind and solar,” the order states. “Reliance on so-called ‘green’ subsidies threatens national security by making the United States dependent on supply chains controlled by foreign adversaries.”

Dear Readers:

As a nonprofit, we are dependent on the generosity of our readers.

Please consider making a small donation of any amount here.

Thank you!

Former President Joe Biden established massive green energy subsidies under his signature 2022 Inflation Reduction Act (IRA), which did not receive a single Republican vote.

The reconciliation package did not immediately terminate Biden-era federal subsidies for green energy technology, phasing them out over time instead, though some policy experts argued that drawn-out timelines could lead to an indefinite continuation of subsidies. Trump’s executive order alludes to potential loopholes in the bill, calling for a review by Secretary of the Treasury Scott Bessent to ensure that green energy projects that have a “beginning of construction” tax credit deadline are not “circumvented.”

Additionally, the executive order directs the U.S. to end taxpayer support for green energy supply chains that are controlled by foreign adversaries, alluding to China’s supply chain dominance for solar and wind. Trump also specifically highlighted costs to taxpayers, market distortions and environmental impacts of subsidized green energy development in explaining the policy.

Ahead of the reconciliation bill becoming law, Trump told Republicans that “we’ve got all the cards, and we are going to use them.” Several House Republicans noted that the president said he would use executive authority to enhance the bill and strictly enforce phase-outs, which helped persuade some conservatives to back the bill.

Continue Reading

Trending

X